Press ReleaseView printer-friendly version << Back
Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics
“We welcome Betzy to vTv. Her years of legal expertise and deep experience in life sciences will be valuable to the vTv team,” said
“With the upcoming initiation of our pivotal studies of TTP399, the company is approaching a key inflection point with the potential to become a commercial organization in the coming years,” added
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes and cystic fibrosis related diabetes. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease, renal disease, primary mitochondrial myopathy, and pancreatic cancer. For more information, please visit www.vtvtherapeutics.com.
The statements made in this release may include forward-looking statements regarding (i) diabetes market and other markets, (ii) the development and clinical trial process, regulatory approval process and attributes of investigational and marketed products to treat these diseases and other conditions, and (iii) the future operations, fund-raising activities, expenditures, opportunities and financial performance of
These forward-looking statements are only estimates based upon the information available to
Undue reliance should not be placed on forward-looking statements, which speak only as of the date hereof. Except as required by law, we expressly disclaim any responsibility to publicly update or revise our forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements contained herein are qualified in their entirety by the foregoing cautionary statements.
This release is being provided to you for information purposes only. This release does not constitute an offer or sale of (or the solicitation of an offer to buy) any securities of
This release should not be relied upon for making any investment decision with respect to any securities of
Selina Husain / Robert Flamm, Ph.D.
firstname.lastname@example.org / email@example.com
Source: vTv Therapeutics Inc.